Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance
about
sameAs
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaAsparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis)Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaStructural and Kinetic Characterization of Guinea Pig l -Asparaginase Type IIICrystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding siteHypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cellsKnockdown of asparagine synthetase A renders Trypanosoma brucei auxotrophic to asparagineFrom Krebs to clinic: glutamine metabolism to cancer therapy.Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing propertiesTHE ANTICOAGULANT AND ANTILYMPHOMA PROPERTIES OF ARSENIC AZOPROTEINS : I. ANTICOAGULANT EFFECTS OF ARSENIC AZOPROTEINS IN VIVO AND IN VITRO: COMPARISON OF ARSENICALS AS ANTICOAGULANTS AND AS ANTILYMPHOMA AGENTS: MOLECULAR STRUCTURE IN RELATION TO ANAlterations in protein and nucleic acid metabolism of lymphoma 6C3HED-og cells in mice given guinea pig serum.Suppression of murine leukemias by L-asparaginase. Incidence of sensitivity among leukemias of various types: comparative inhibitory activities of guinea pig serum L-asparaginase and Escherichia coli L-asparaginase.Isozymes of acid phosphatase in normal and Calmette-Guérin bacillus-induced rabbit alveolar macrophagesStructural Insight into Substrate Selectivity of Erwinia chrysanthemi L-asparaginaseProduction of L-asparaginase II by Escherichia coliPEG-asparaginase.Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.Conditions for the production of L-asparaginase 2 by coliform bacteria.L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo.The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificityL-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia.The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia.L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.A critical review on properties and applications of microbial l-asparaginases.Drug-induced amino acid deprivation as strategy for cancer therapy.Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.Asparaginase pharmacology: challenges still to be faced.Enzymes in cancer. Asparaginase from chicken liverBiochemical Underpinnings of Immune Cell Metabolic Phenotypes.A novel L-asparaginase from Aquabacterium sp. A7-Y with self-cleavage activation.L-asparaginase production by Erwinia aroideae.Binding of asparaginase to mouse monocytes.Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes.The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia.The role of leukocytes and their hydrolases in the persistence, degradation, and transport of bacterial constituents in tissues: relation to chronic inflammatory processes in staphylococcal, streptococcal, and mycobacterial infections and in chronicL-Asparaginase activity in human and animal sera.In silico analysis of L-asparaginase from different source organisms.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.
P2860
Q26738640-8CF94BB3-DA61-4DCA-81D1-64D663C9F3E5Q26801165-6834A42B-9981-4B73-9046-74D30A9C6381Q26825970-43F548A2-6CF0-4B3C-8762-BB6FFEB22A52Q27682506-A5B37E6E-60FA-4D97-BE3B-065FC3BEC4D3Q27694569-2A281F6E-760D-4F6F-B9E2-DE54982659A9Q28352892-F6C6E8D8-E9C0-4EB7-8EFF-3ECDC4B0E16BQ28536071-0F357F66-075D-4B9B-9402-498765EB2A12Q33834498-87E96899-8BF5-4FB6-AF71-8AEBC3F066EBQ34551046-A18F5640-1158-4E93-BE5D-BD561D1DE3B4Q34580270-28DAA100-15C4-4A8E-A669-EB46E72B392EQ36266716-766FE88B-CFAD-4F57-998B-A3CD1D1A6447Q36267938-78539D27-F389-461D-B7ED-287BE523EC19Q36268663-F2D7D939-71CF-485D-94FE-F3CCE95292BCQ36269390-93779B89-D6FF-4A5F-8ABB-0D1539E7B5FDQ36645799-0C88B632-5772-454F-A46B-CE6D1FCFFB5AQ36851798-97531A94-257D-4904-B47A-53AA2DE56C45Q36909298-273F4ED3-FF43-473A-B452-6824F6F1F35FQ36918761-0F063C84-5E39-4F57-B9F8-09F98C41B584Q37194390-30B373A6-29AD-41E0-9B24-0751D2AF40EBQ37379199-2EB43EAE-1715-49AF-9D16-87E73D5B714EQ37615404-8167B1AC-9663-4E6E-8DA5-DAFD5627C702Q38017602-C702AF0E-F811-4B48-AE0A-0203F7AD626AQ38055656-E8EFF77C-B29F-4EE1-8C5F-E5D24B4D742CQ38105626-E04F537A-B1DC-4E88-A29F-9041EE73A91CQ38417141-F1C9A24F-BC5F-4BF8-8F66-B84B8C6599D4Q38657061-E203625C-64A6-4EE2-A56E-9871B0FE4B6BQ38696311-63B2D6FE-D619-4BBE-9DF1-5CE076FF7BCBQ39135887-5220406A-5B86-43C6-A491-294FB7DEEC77Q39266681-644F4CA8-72E4-49C2-A9B7-C71C9036445FQ39313207-CFD238A5-F501-49E3-B1AA-605BC0C70C03Q40301514-8FAFC7D7-E61D-4A19-81F1-42C7E8C78D83Q40718823-6A02E6D4-AA7C-464A-8CF6-23099872EB46Q41156574-393F9485-5CAE-44DE-9969-E58075CBCF83Q42083533-8E83566E-2BEE-4292-806D-AA98C9A2BB50Q44291604-B2827E83-9045-4140-9CB3-BB3860ABBF97Q45183552-3A79A7FF-AEFA-4640-991A-A5912BBF8DD6Q46796451-233DC3EC-E5F1-4E8E-9808-8F2F1D194EC8Q46845540-81B9186F-09DF-4BAA-8852-268E62EF3DA9Q48166631-9899F232-020A-42EB-A59A-13D431FD18D8Q50143850-325F0803-79C5-4B7C-B54E-3ABA1748690B
P2860
Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance
description
1963 nî lūn-bûn
@nan
1963 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1963 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1963年の論文
@ja
1963年論文
@yue
1963年論文
@zh-hant
1963年論文
@zh-hk
1963年論文
@zh-mo
1963年論文
@zh-tw
1963年论文
@wuu
name
Evidence that the L-asparagina ...... of the antilymphoma substance
@ast
Evidence that the L-asparagina ...... of the antilymphoma substance
@en
Evidence that the L-asparagina ...... of the antilymphoma substance
@nl
type
label
Evidence that the L-asparagina ...... of the antilymphoma substance
@ast
Evidence that the L-asparagina ...... of the antilymphoma substance
@en
Evidence that the L-asparagina ...... of the antilymphoma substance
@nl
altLabel
EVIDENCE THAT THE L-ASPARAGINA ...... OF THE ANTILYMPHOMA SUBSTANCE
@ast
EVIDENCE THAT THE L-ASPARAGINA ...... OF THE ANTILYMPHOMA SUBSTANCE
@en
prefLabel
Evidence that the L-asparagina ...... of the antilymphoma substance
@ast
Evidence that the L-asparagina ...... of the antilymphoma substance
@en
Evidence that the L-asparagina ...... of the antilymphoma substance
@nl
P2860
P3181
P356
P1476
EVIDENCE THAT THE L-ASPARAGINA ...... OF THE ANTILYMPHOMA SUBSTANCE
@en
Evidence that the L-asparagina ...... of the antilymphoma substance
@en
P2093
J D BROOME
J. D. Broome
P2860
P304
P3181
P356
10.1084/JEM.118.1.99
P407
P577
1963-07-01T00:00:00Z